Literature DB >> 33263172

Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.

S Greten1, J I Müller-Funogea2, O Krause3, M Klietz2, F Wegner2, G U Höglinger2, N Simon4, U Junius-Walker3, S Gerbel4.   

Abstract

To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medication appropriateness in PD inpatients applying the FORTA list and drug-drug interaction software, further to assess the adequacy of FORTA list for patients with PD. We retrospectively collected demographic data, comorbidities, laboratory values, and the medication from the discharge letters of 123 geriatric inpatients with PD at the university hospital of Hannover Medical School. Patients suffered on average from 8.2 comorbidities. The majority of the medication was labeled A (60.6% of PD-specific and 40.9% of other medication) or B (22.3% of PD-specific and 26.9% of other medication). Administered drugs labeled with D were amantadine, clozapine, oxazepam, lorazepam, amitriptyline, and clonidine. Overall, 545 interactions were identified, thereof 11.9% severe interactions, and 1.7% contraindicated combinations. 81.3% of patients had at least one moderate or severe interaction. The FORTA list gives rational recommendations for PD-specific and other medication, especially for general practitioners. Considering the demographic characteristics and the common multimorbidity of geriatric PD patients, this study underlines the importance of awareness, education, and preventive interventions to increase drug safety.

Entities:  

Keywords:  Drug safety; FORTA prescribing list; Geriatric patients; Multimorbidity; Parkinson’s disease; Polypharmacy

Mesh:

Substances:

Year:  2020        PMID: 33263172      PMCID: PMC7815558          DOI: 10.1007/s00702-020-02276-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  73 in total

Review 1.  Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine.

Authors:  M H Beers; J G Ouslander; I Rollingher; D B Reuben; J Brooks; J C Beck
Journal:  Arch Intern Med       Date:  1991-09

2.  Emergency hospitalizations for adverse drug events in older Americans.

Authors:  Daniel S Budnitz; Maribeth C Lovegrove; Nadine Shehab; Chesley L Richards
Journal:  N Engl J Med       Date:  2011-11-24       Impact factor: 91.245

Review 3.  Advances in Pharmacotherapy of Late-Life Depression.

Authors:  John L Beyer; Kim G Johnson
Journal:  Curr Psychiatry Rep       Date:  2018-04-07       Impact factor: 5.285

4.  Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.

Authors:  Rupam Borgohain; Jozsef Szasz; Paolo Stanzione; Chandrashekhar Meshram; Mohit H Bhatt; Dana Chirilineau; Fabrizio Stocchi; Valentina Lucini; Rodolfo Giuliani; Emma Forrest; Patricia Rice; Ravi Anand
Journal:  Mov Disord       Date:  2014-07-10       Impact factor: 10.338

5.  Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.

Authors:  Willi Cawello; Sascha Ahrweiler; Wladyslaw Sulowicz; Agnieszka Szymczakiewicz-Multanowska; Marina Braun
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

6.  The Use of Benzodiazepine Receptor Agonists and the Risk of Hospitalization for Pneumonia: A Nationwide Population-Based Nested Case-Control Study.

Authors:  Tien-Yu Chen; John W Winkelman; Wei-Chung Mao; Chia-Lin Liu; Chung-Yao Hsu; Chi-Shin Wu
Journal:  Chest       Date:  2017-08-04       Impact factor: 9.410

7.  Marked effect of liver and kidney function on the pharmacokinetics of selegiline.

Authors:  Markku Anttila; Eero A Sotaniemi; Olavi Pelkonen; Arja Rautio
Journal:  Clin Pharmacol Ther       Date:  2005-01       Impact factor: 6.875

8.  Escitalopram in the acute treatment of depressed patients aged 60 years or older.

Authors:  Anjana Bose; Dayong Li; Chetan Gandhi
Journal:  Am J Geriatr Psychiatry       Date:  2008-01       Impact factor: 4.105

9.  Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis.

Authors:  Melinda J Barker; Kenneth M Greenwood; Martin Jackson; Simon F Crowe
Journal:  Arch Clin Neuropsychol       Date:  2004-04       Impact factor: 2.813

View more
  5 in total

1.  One Year Trajectory of Caregiver Burden in Parkinson's Disease and Analysis of Gender-Specific Aspects.

Authors:  Martin Klietz; Hannah von Eichel; Theresa Schnur; Selma Staege; Günter U Höglinger; Florian Wegner; Stephanie Stiel
Journal:  Brain Sci       Date:  2021-02-26

2.  Patient Safety in a Box: Implementation and Evaluation of the Emergency Box in Geriatric and Parkinson Patients.

Authors:  Lea Krey; Pia Lange; Anh Thu Tran; Stephan Greten; Günter U Höglinger; Florian Wegner; Olaf Krause; Martin Klietz
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

Review 3.  Disease modification in Parkinsonism: obstacles and ways forward.

Authors:  M Höllerhage; M Klietz; G U Höglinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-13       Impact factor: 3.850

4.  Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study.

Authors:  Martin Schulze Westhoff; Adrian Groh; Sebastian Schröder; Phileas Johannes Proskynitopoulos; Kirsten Jahn; Martin Klietz; Benjamin Krichevsky; Dirk O Stichtenoth; Felix Wedegärtner; Stefan Bleich; Helge Frieling; Johannes Heck
Journal:  J Neural Transm (Vienna)       Date:  2022-09-02       Impact factor: 3.850

5.  Prevalence of QTc Prolongation in Patients with Parkinson's Disease. Assessment of the Effects of Drugs, Clinical Risk Factors and Used Correction Formula.

Authors:  Jakub J Malkiewicz; Maciej Malkiewicz; Joanna Siuda
Journal:  J Clin Med       Date:  2021-03-31       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.